Abbott Laboratories (ABT)财务
NYSE · Healthcare · Medical - Devices · 员工115,000人 · CEO Robert Ford
- 股价
- $106.20 +1.56%
- 市值
- $1840亿
- 企业价值
- $2110亿
- 最近财报
- Q3 '26 2026-09-30提交
- 下次财报
- 2027-01-28 EPS预期 $1.64
营收(TTM)$482亿+10.0% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)15.2%-2.5 百分点 对比去年同期营业利润 $73.5亿
净利润(TTM)$47亿-66.4% 对比去年同期税后,含营业外收益
自由现金流(TTM)–– 对比去年同期资本支出 –
稀释EPS(TTM)$2.70-66.2% 对比去年同期最近4个季度之和
净现金-$270亿-338.7% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $1840亿 EV $2110亿
- 营收
- $482亿 过去12个月
- 营收增速
- +13% FY2026年一致预期
- 净利润率
- 9.7% 净利润 / 营收,TTM
- P/E
- 39.3× 预期 19.2×(FY2026)
- P/S
- 3.8× 股价 / 营收,TTM
- EV / EBITDA
- 21.8× TTM
- 自由现金流
- – 过去12个月
- 净利润
- $47亿 过去12个月
- 营收预期
- $500亿 FY2026年一致预期
- 盈利
- 2027-01-28 营收预期 $132亿
- 股息
- $2.52 每股,过去12个月
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-21):营收符合预期,EPS 符合预期营收$130亿,预期$130亿(+0.2%);EPS $1.42,预期$1.42(0.0%)。
- 营收增长加速:同比14.5%Q3 '26营收$130亿,此前四个季度的平均值为8.0%。
- 营业利润率15.2%(TTM),较去年同期-2.5 百分点营收增长10.0%,营业利润增长-5.6%。
- 税前利润的12.0%被营业外亏损吞噬税前利润$65.6亿,营业利润$73.5亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 稀释股数一年内减少0.6%Q3 '26稀释股数17.4亿,一年前为17.5亿。
- 净债务 $270亿现金 + 短期投资 $56亿,含租赁债务 $326亿;一年前净债务 $61.6亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $130亿 | $114亿 | +14.5% |
| 毛利率 | 57.1% | 55.7% | +1.3 百分点 |
| 营业利润 | $14.8亿 | $20.6亿 | -28.2% |
| 营业利润率 | 11.3% | 18.1% | -6.8 百分点 |
| 净利润 | $9.2亿 | $16.4亿 | -44.0% |
| 稀释EPS | $0.53 | $0.94 | -43.6% |
| 经营现金流 | – | $27.9亿 | – |
| 资本支出 | – | $4.96亿 | – |
| 自由现金流 | – | $22.9亿 | – |
| R&D | $9.08亿 | $7.85亿 | +15.7% |
| 股权激励费用 | – | $1.2亿 | – |
实际 vs 一致预期
2026-10-21| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $130亿 | $130亿 | +0.2% |
| EPS(一致预期口径) | $1.42 | $1.42 | 0.0% |
来自2026-10-21发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Diagnostic Products | $30.9亿 | -47.6% | 24.6% | $113亿 | -12.5% | |
| Medical Devices | $58.5亿 | +9.0% | 46.5% | $225亿 | +12.2% | |
| Nutritional Products | $21.4亿 | -3.1% | 17.0% | $82.5亿 | -3.5% | |
| Established Pharmaceutical Products | $15亿 | +8.4% | 11.9% | – | – | |
| Established Pharmaceuticals | – | – | – | – | – | |
| Other | $500万 | – | 0.0% | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Non-US | $73.8亿 | +7.4% | 58.6% | $213亿 | -18.3% | |
| United States | $52.2亿 | +22.0% | 41.4% | $182亿 | +7.0% |
分部利润
取自每份10-Q / 10-K分部附注的各披露分部营业利润(多数数据源缺少的利润拆分)。
Q2 '26分部
| 分部 | 营收 | 同比 | 营业利润 | 同比 | 利润率 | 去年同期利润率 | TTM营业利润 |
|---|---|---|---|---|---|---|---|
| Established Pharmaceutical Products | – | – | $3.82亿 | +10.4% | – | – | $13.9亿 |
| Nutritional Products | – | – | $3.68亿 | -12.0% | – | – | $14.3亿 |
| Diagnostic Products | – | – | $4.99亿 | +34.1% | – | – | $18.4亿 |
| Medical Devices | – | – | $19.7亿 | +9.6% | – | – | $76.7亿 |
各分部营业利润
季度各分部营业利润率
季度第四季度为推算值:10-K披露全年数据,减去10-Q的前三个季度。
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 自由现金流
- –
- 股东回报 / FCF
- –
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 39.3× | 29.0× | 14.7× – 35.5× |
| EV / EBITDA | 21.8× | 18.9× | 16.9× – 21.3× |
| EV / 营收 | 4.4× | 5.1× | 4.6× – 6.0× |
| 股价 / FCF | 21.1× | 30.3× | 24.7× – 37.7× |
| 股价 / 净资产 | 3.6× | 5.1× | 4.1× – 7.0× |
| FCF收益率 | 4.7% | 3.4% | 2.7% – 4.1% |
| 投入资本回报率 | 5.6% | 10.3% | 8.4% – 12.6% |
| 净资产收益率 | 9.1% | 18.8% | 12.5% – 28.1% |
分析师
一致目标价 $121.36 (+14.3%)
区间 $112.00 – $130.00 · 评级 Buy
强烈买入0
买入33
持有10
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $500亿 | +12.8% | $5.52 | +48.3% | 19.2× | 17 |
| FY2027 | $537亿 | +7.4% | $5.93 | +7.6% | 17.9× | 18 |
| FY2028 | $571亿 | +6.5% | $6.50 | +9.5% | 16.3× | 14 |
| FY2029 | $614亿 | +7.5% | $7.21 | +10.8% | 14.7× | 7 |
| FY2030 | $658亿 | +7.1% | $7.94 | +10.2% | 13.4× | 11 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Abbott Laboratories在近期10-Q / 10-K文件中标记的全部232项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Trade, Current | $46.8亿 | $42.1亿 | +11.0% | $42.4亿 | $42亿 | +1.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $82.1亿 | $73.3亿 | +12.1% | $79.3亿 | $69.3亿 | +14.5% |
| Accounts Receivable, Allowance for Credit Loss | $3.1亿 | $2.59亿 | +19.7% | $2.9亿 | $2.47亿 | +17.4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $4.94亿 | $4.49亿 | +10.0% | $4.9亿 | $4.39亿 | +11.6% |
| Accounts Receivable, Allowance for Credit Loss, Writeoff | $600万 | $1100万 | -45.5% | $3200万 | $5500万 | -41.8% |
| Accounts Receivable, Credit Loss Expense (Reversal) | $2600万 | $2300万 | +13.0% | $7500万 | $6100万 | +23.0% |
| Accrued Income Taxes, Current | $5.98亿 | $4.85亿 | +23.3% | $5.69亿 | $5.94亿 | -4.2% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $134亿 | $125亿 | +7.0% | $134亿 | $121亿 | +11.0% |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | $1400万 | $5.81亿 | -97.6% | $100万 | $6.11亿 | -99.8% |
| Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | -$63.3亿 | -$69.6亿 | +9.0% | -$59.3亿 | -$75.1亿 | +21.0% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$63.1亿 | -$74.2亿 | +14.9% | -$60亿 | -$79.1亿 | +24.1% |
| Amortization of Intangible Assets | $4.22亿 | $4.2亿 | +0.5% | $16.8亿 | $18.8亿 | -10.4% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 990万 | 143万 | +591.8% | 100万 | 700万 | -85.7% |
| AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax | $3300万 | $1.19亿 | -72.3% | -$6900万 | $2.1亿 | -132.9% |
| Assets | $1100亿 | $814亿 | +35.6% | $867亿 | $814亿 | +6.5% |
| Assets, Current | $255亿 | $232亿 | +10.2% | $260亿 | $237亿 | +9.9% |
| Assets, Fair Value Disclosure | $5.75亿 | – | – | $4.5亿 | $7.14亿 | -37.0% |
| Buildings and Improvements, Gross | $45.4亿2025-12-31 | $42.1亿 | +8.0% | $45.4亿 | $42.1亿 | +8.0% |
| Business Combination, Contingent Consideration, Liability | $3.04亿 | – | – | $100万 | $3800万 | -97.4% |
| Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $9600万 | – | – | – | – | – |
| Cash and Cash Equivalents, at Carrying Value | $68亿 | $65.3亿 | +4.1% | $85.2亿 | $76.2亿 | +11.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $68亿 | $65.3亿 | +4.1% | $85.2亿 | $76.2亿 | +11.9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$17.2亿 | -$10.8亿 | -58.6% | $9.06亿 | $7.2亿 | +25.8% |
| Common Stock, Dividends, Per Share, Declared | $0.63 | $0.59 | +6.8% | $2.40 | $2.24 | +7.1% |
| Common Stock, Shares Authorized | 24亿 | 24亿 | 0.0% | 24亿 | 24亿 | 0.0% |
| Common Stock, Shares, Issued | 20亿 | 20亿 | +0.1% | 20亿 | 19.9亿 | +0.3% |
| Common Stock, Value, Issued | $254亿 | $251亿 | +0.9% | $255亿 | $252亿 | +1.5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $7.66亿 | $18.1亿 | -57.8% | $84.3亿 | $133亿 | -36.8% |
| Construction in Progress, Gross | $25.7亿2025-12-31 | $24.9亿 | +3.2% | $25.7亿 | $24.9亿 | +3.2% |
| Contract with Customer, Liability | $6.6亿 | $6.01亿 | +9.8% | $6.33亿 | $5.68亿 | +11.4% |
| Contract with Customer, Liability, Revenue Recognized | $1.23亿 | $9900万 | +24.2% | -$4.23亿 | -$4.6亿 | +8.0% |
| Cost of Goods and Services Sold | $48.9亿 | $44.7亿 | +9.4% | $193亿 | $187亿 | +3.3% |
| Costs and Expenses | $98.2亿 | $86.7亿 | +13.3% | $363亿 | $351亿 | +3.3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $3.02亿 | – | – |
| Current Federal, State and Local, Tax Expense (Benefit) | – | – | – | $8500万 | $4.97亿 | -82.9% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $11.1亿 | $10.8亿 | +3.6% |
| Current Income Tax Expense (Benefit) | – | – | – | $15亿 | $15.7亿 | -4.5% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $4.97亿 | -100.0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$2.17亿 | – | – |
| Deferred Federal, State and Local, Tax Expense (Benefit) | – | – | – | -$4000万 | -$4.59亿 | +91.3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $6.98亿 | -$75亿 | +109.3% |
| Deferred Income Tax Expense (Benefit) | – | – | – | $4.41亿 | -$79.6亿 | +105.5% |
| Deferred Income Taxes and Other Assets, Noncurrent | $184亿 | $168亿 | +9.0% | $184亿 | $165亿 | +11.9% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | -$4.59亿 | +100.0% |
| Deferred Tax Assets, Gross | $116亿2025-12-31 | $121亿 | -3.9% | $116亿 | $121亿 | -3.9% |
| Deferred Tax Assets, in Process Research and Development | $9.02亿2025-12-31 | $7.73亿 | +16.7% | $9.02亿 | $7.73亿 | +16.7% |
| Deferred Tax Assets, Inventory | $1.46亿2025-12-31 | $1.68亿 | -13.1% | $1.46亿 | $1.68亿 | -13.1% |
| Deferred Tax Assets, Net | $75.1亿2025-12-31 | $81.1亿 | -7.5% | $75.1亿 | $81.1亿 | -7.5% |
| Deferred Tax Assets, Net of Valuation Allowance | $98.3亿2025-12-31 | $104亿 | -5.5% | $98.3亿 | $104亿 | -5.5% |
| Deferred Tax Assets, Other | $97.3亿2025-12-31 | $104亿 | -6.0% | $97.3亿 | $104亿 | -6.0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | $2.27亿2025-12-31 | $2.3亿 | -1.3% | $2.27亿 | $2.3亿 | -1.3% |
| Deferred Tax Assets, Valuation Allowance | $17.7亿2025-12-31 | $16.6亿 | +6.4% | $17.7亿 | $16.6亿 | +6.4% |
| Deferred Tax Liabilities, Gross | $23.3亿2025-12-31 | $23亿 | +1.3% | $23.3亿 | $23亿 | +1.3% |
| Deferred Tax Liabilities, Other | $10.6亿2025-12-31 | $13.7亿 | -22.6% | $10.6亿 | $13.7亿 | -22.6% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $4.89亿2025-12-31 | $4.08亿 | +19.9% | $4.89亿 | $4.08亿 | +19.9% |
| Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $12.8亿2025-12-31 | $11.8亿 | +8.1% | $12.8亿 | $11.8亿 | +8.1% |
| Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets | $1.52亿2025-12-31 | $1.49亿 | +2.0% | $1.52亿 | $1.49亿 | +2.0% |
| Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $12.8亿2025-12-31 | $11.8亿 | +8.1% | $12.8亿 | $11.8亿 | +8.1% |
| Defined Benefit Plan, Plan Assets, Amount | $166亿2025-12-31 | $144亿 | +15.0% | $166亿 | $144亿 | +15.0% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation | $12亿2025-12-31 | $11.1亿 | +7.6% | $12亿 | $11.1亿 | +7.6% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标、预期:Financial Modeling Prep。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-01